Equatorial GuineaTuberculosis profile
Population  2017 1.3 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.28 (0.2–0.38) 22 (16–30)
Mortality (HIV+TB only) 0.34 (0.26–0.43) 27 (21–34)
Incidence  (includes HIV+TB) 2.4 (2.1–2.7) 191 (167–216)
Incidence (HIV+TB only) 0.95 (0.79–1.1) 75 (63–88)
Incidence (MDR/RR-TB)** 0.1 (0.057–0.16) 8 (4.5–12)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.13 (0.13–0.14) 0.88 (0.81–0.95) 1 (0.93–1.1)
Males 0.15 (0.14–0.15) 1.3 (1.1–1.4) 1.4 (1.3–1.5)
Total 0.28 (0.27–0.29) 2.1 (1.9–2.4) 2.4 (2.1–2.7)
TB case notifications, 2017  
Total cases notified 1 444
Total new and relapse 1 444
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 69%
          - % pulmonary 88%
          - % bacteriologically confirmed among pulmonary 70%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 60% (53–68)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.26 (0.2–0.32)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 390 39%
          - on antiretroviral therapy 306 78%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  67
(45–89)
Estimated % of TB cases with MDR/RR-TB 2.5% (1.1–4.3) 29% (21–39)  
% notified tested for rifampicin resistance 1% 100% 150
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 31, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 31, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 89% 1 369
Previously treated cases, excluding relapse, registered in 2016 78% 59
HIV-positive TB cases registered in 2016 77% 395
MDR/RR-TB cases started on second-line treatment in 2015 95% 22
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-25 Data: www.who.int/tb/data